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The activation of the HIV-1 long terminal repeat (LTR) by the viral transcriptional transactivator Tat is an essential step in
the viral replication cycle. To increase the processivity of RNA polymerase II, Tat interacts with the positive transcription
elongation factor b (P-TEFb) and cyclin-dependent kinase (CDK)-activating kinase (CAK). In this study, we demonstrate that
a pseudo-substrate peptide for CDK7, mC2p, inhibits HIV-1 replication as well as Tat transactivation. Specifically, mC2p
blocks only the activity of CAK and not that of P-TEFb. Moreover, mC2p inhibits Tat transactivation and HIV replication.
Therefore, the activation of CDK7 by Tat is considered a critical step of Tat transactivation and mC2p and related compounds
represent potential candidates for novel anti-HIV therapeutics. © 2000 Academic Press
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tINTRODUCTION
Tat is an essential regulatory protein of HIV-1 replica-
tion and plays a major role in the pathogenesis of AIDS
(Jones and Peterlin, 1994; Cullen, 1993; Okamoto, 1995;
Gallo, 1999). By interacting with its RNA target, TAR
(transactivation response) element, Tat activates tran-
scription from the HIV-1 long terminal repeat (LTR) (So-
rodski et al., 1985; Cullen, 1986; Okamoto and Wong-
Staal, 1986; Kao et al., 1987). Tat increases the rate of
transcriptional elongation by increasing the processivity
of RNA polymerase II (RNAP II) (Kao et al., 1987; Laspia
et al., 1989). This function requires the carboxyl terminal
domain (CTD) of RNAP II and CTD kinases (Okamoto et
al., 1996; Hermann et al., 1996; Yang et al., 1996; Chun et
al., 1996). CDK7 is a CTD kinase and is a component of
the cyclin-dependent kinase (CDK)-activating kinase
(CAK) complex in the basal transcription factor IIH
(TFIIH). Tat interacts with CDK7 and increases its kinase
activity (Parada et al., 1996; Cujec et al., 1997a; Garcia-
Martinez et al., 1997a; Nekhai et al., 1997). The inhibition
of CDK7 by mC2p (mutant pseudo-substrate mimicking
the target peptide sequence on CDK2) also blocked Tat
transactivation (Cujec et al., 1997a). Tat also interacts
with CDK9, which is a component of the positive tran-
scription elongation factor P-TEFb (Garriga et al., 1996;
Jones, 1997; Yang et al., 1997; Zhu et al., 1997; Mancebo
et al., 1997; Peng et al., 1998; Zhou et al., 1998; Wei et al.,
1998). Cyclin T1 in P-TEFb complex has been identified
as the cellular cofactor for the binding of Tat to TAR RNA
(Wei et al., 1998; Bieniasz et al., 1998; Garber et al., 1998).
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 81-52-859-1235. E-mail: tokamoto@med.nagoya-cu.ac.jp.
337After binding to TAR, P-TEFb hyperphosphorylates the
CTD and thus promotes the steps of transcription from
initiation to elongation. However, it remains to be deter-
mined whether phosphorylation of CTD by TFIIH (CDK7)
and P-TEFb (CDK9) has distinct or redundant roles in Tat
transactivation.
In this study we examined the role of CAK on Tat
transactivation and HIV-1 replication by using a pseudo-
substrate peptide mC2p and its derivative fused with
nuclear localization sequence (NLS). We also examined
whether Tat stimulates the activity of P-TEFb and
whether mC2p could block the activity of P-TEFb using
an in vitro reconstituted system. Our data demonstrate
that the specific inhibition of CDK7 by mC2p is sufficient
in blocking Tat transactivation and viral replication.
These observations suggest that CAK is a possible tar-
get for anti-HIV therapeutics.
RESULTS
NLS-mC2p does not inhibit the activity of
CDK9 in vitro
It is known that the kinase activity can be efficiently
inhibited by excess amounts of substrate peptides con-
taining a mutation in the target amino acid residue
(Poteet-Smith et al., 1997). Since CAK (CDK7) phosphor-
ylates the threonine residue of CDK2 at position 160, we
designed mC2p by replacing threonine with alanine
(Fisher et al., 1994, 1995; Makela et al., 1994). It was
reviously shown that mC2p could block Tat transactiva-
ion in vitro (Cujec et al., 1997a). However, biochemical
and genetic evidence have indicated that P-TEFb is crit-
ical for Tat transactivation (Garriga et al., 1996; Jones,
1996; Yang et al., 1997; Zhu et al., 1997; Mancebo et al.,
0042-6822/00 $35.00
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338 OKAMOTO ET AL.1997; Wei et al., 1998). It was not clear whether mC2p
could also block P-TEFb. Thus, we first examined the
effect of mC2p on the activity of P-TEFb (CDK9) using an
in vitro reconstituted system with purified P-TEFb com-
plex and recombinant GST-CTD protein as the substrate.
Figure 1A (lower panel) shows that Tat could activate the
CAK activity, which was blocked by mC2p in vitro as
previously reported (Cujec et al., 1997a). When we per-
FIG. 1. The peptide inhibitor mC2p does not inhibit the CTD kinase
activity of P-TEFb in vitro. (A) Effects of mC2p on the CTD kinase activity
of P-TEFb and CAK. Kinase reactions using GST-CTD as a substrate
were performed with recombinant CAK or immunopurified P-TEFb,
either in the presence or the absence of Tat (2 ng/ml). Various amounts
of mC2p were added. Note that Tat could activate CAK but not P-TEFb.
(B) The histone H1 kinase activity of CDK2 and the effects of CAK and
P-TEFb. The top panel illustrates the experimental scheme. The immu-
noprecipitated cyclin AD171/CDK2HA complex, in which CDK2 was
tagged with HA epitope, was incubated with either CAK or P-TEFb and
CDK2 kinase activity was detected by its activity of histone H1 phos-
phorylation as described under Materials and Methods.formed a similar experiment with P-TEFb, the activity of NP-TEFb was not augmented by Tat and no effect was
detected with mC2p (Fig. 1A, upper panel). Whereas CAK
stimulated the activity of CDK2 in phosphorylating his-
tone H1, P-TEFb did not activate the CDK2 activity, which
is consistent with the inability of mC2p to block P-TEFb
(Fig. 1B). We thus concluded that Tat can activate CDK7
but not CDK9 and that mC2p appears to be a specific
inhibitor of CDK7.
The nuclear localization of mC2p is necessary for
blocking the Tat transactivation
To efficiently deliver mC2p into the cell nucleus, we
created the NLS-mC2p peptide containing an additional
sequence corresponding to NLS derived from SV40 T
antigen (Fig. 2A). These peptides were FITC-labeled,
introduced into COS cells, and their localizations were
examined by fluorescence microscopy (Fig. 2B). Both
NLS-mC2p and NLS-rC2p (containing the randomized
mC2p sequence fused with NLS) were found most pre-
dominantly in the nucleus, while mC2p without NLS was
retained in the cytoplasm. These data indicate that the
NLS could effectively deliver the peptide to the nucleus.
As shown in Fig. 2C, NLS-mC2p had no effect on the
basal transcription from the HIV-1 LTR or the immediate
early promoter of CMV. However, when Tat-mediated
transactivation was examined, there was a dose-depen-
dent suppression of gene expression by NLS-mC2p. The
transactivation was suppressed to almost close to the
basal level by the highest concentration of NLS-mC2p (in
liposome) (Fig. 2D). No effect was observed with mC2p
or NLS-rC2p.
Inhibition of HIV-1 production from COS cells
transfected with the HIV-1 provirus clone
by NLS-mC2p
Since NLS-mC2p inhibited Tat transactivation, we next
examined its effect on HIV-1 replication. NLS-mC2p was
introduced into COS cells together with a plasmid con-
taining the full-length HIV-1HXB2 or HIV-1NL4–3 sequence
(Fig.3). After incubation for 48 h, supernatants were col-
lected and measured for the viral p24 gag antigen level
for quantitation of HIV-1 production. As presented in
Fig.3A, NLS-mC2p, but not NLS-rC2p, inhibited HIV-1
production in a dose-dependent manner. There was no
significant difference in the susceptibility of either HIV-1
clone to the effect of NLS-mC2p. None of the peptides
with concentrations up to 40 mM (in liposome solution)
howed any significant cytotoxicity as measured by the
TT assay (Fig. 3B).
IV-1 production is also inhibited by mC2p-encoding
lasmid
To confirm the inhibitory effect of NLS-mC2p, we con-
tructed a plasmid, pEGFP-NLS-mC2p, which encodes
LS-mC2p linked to the green fluorescence protein
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339HIV-1 REPLICATION INHIBITED BY PSEUDO-SUBSTRATE PEPTIDE(GFP). The effect of pEGFP-NLS-mC2p on HIV-1 replica-
tion was evaluated by the amount of virus production in
the supernatant of COS cells which were cotransfected
with a plasmid containing a full-length HIV-1 provirus
(HIV-1HXB2 or HIV-1NL4–3) (Fig. 4). As demonstrated in
Fig.4A, pEGFP-NLS-mC2p inhibited the viral production
in a dose-dependent manner. On the other hand, the
control plasmid pEGFP-NLS-rC2p did not show any ef-
fect. Both pEGFP-NLS-mC2p and pEGFP-NLS-rC2p had
only marginal cytotoxicity on the cell, even at the highest
amount (0.8 mg) used for transfection (Fig. 4B). Micro-
copic examinations of the GFP fluorescence confirmed
he nuclear localization of the EGFP-NLS-mC2p and
GFP-NLS-rC2p in the transfected cells (data not
hown).
Finally, to further confirm the effects of NLS-mC2p, we
FIG. 2. Inhibition of Tat transactivation by a pseudo-substrate peptide
of threonine 160 by alanine. To target the peptide to the nucleus, we fur
(termed “NLS-mC2p”). NLS-peptide containing a random sequence with
(B) Localization of NLS-containing peptides in the nucleus. The synthe
liposome. After 48 h of the liposome-mediated peptide transfer, intracel
treatment, the same cells were photographed with different filters. PI, pr
promoter activities. Various amounts of the NLS-mC2p were transferred
containing HIV-1 LTR fused to CAT gene or pCMVCAT containing the im
those in the liposome. (D) Suppression of Tat transactivation by NLS
transferred into COS cells using a liposome together with a reporte
amounts of Tat protein were expressed in these cells as detected by
obtained from at least three independent experiments.stablished stable Jurkat cells, clones 5, 11, and 18,xpressing EGFP-NLS-mC2p and examined their sus-
eptibility for viral replication. They were infected with
IV-1HE or HIV-1IIIB and the viral replication was assessed
by measuring the level of virion-associated p24 gag
antigen in the culture supernatant (Figs. 4C and 4D).
Parental Jurkat cells were susceptible for replication of
HIV-1HE or HIV-1IIIB. In contrast, cells expressing NLS-
mC2p were resistant to HIV-1 replication. These data
confirmed the previous findings that NLS-mC2p could
block HIV-1 replication.
DISCUSSION
Several lines of evidence have suggested that the
phosphorylation of the CTD is required for the transcrip-
tional elongation of RNAPII. It is regulated by various
e mC2p was derived from human CDK2 (149–170 aa) with substitution
dified mC2p by adding the nuclear localization signal (NLS) sequence
e amino acid composition as mC2p, NLS-rC2p, was used as a control.
tides were labeled with FITC and introduced into COS cells by using
alization was examined by fluorescence microscopy. For each peptide
iodide staining. (C) Effects of NLS-mC2p on basal HIV-1-LTR and CMV
OS cells using a liposome together with a reporter plasmid, pHIVSCAT,
te early promoter from CMV. Concentrations of the peptide shown are
Various concentrations of the mC2p, NLS-mC2p, or NLS-rC2p were
id, pHIVSCAT, and pSVHATAT, a Tat-expressing plasmid. Equivalent
n blot (data not shown). All data represent the means and SD values. (A) Th
ther mo
the sam
tic pep
lular loc
opidium
into C
media
-mC2p.
r plasmCTD kinases and phosphatases, which are linked to the
i
t
O
n
M
a
e
T
r
G
p
1
R
p
s
o
b
l
a
k
p
i
T
D
T
a
a
a
t
t
p
a
t
v
r
t
l
c
P
g
s
c
(
n
a
e
l
p
s
R
m
p
a
w
a
t
f
340 OKAMOTO ET AL.cycle of initiation, elongation, and termination of tran-
scription (Dahmus, 1996). CTD kinase activities have
been identified with multiprotein complexes such as
TFIIH and P-TEFb, which might play distinct roles at
different steps of the transcription by RNAPII: TFIIH and
P-TEFb are required for promoter clearance and the
elongation of transcription, respectively. However, before
the formation of the preinitiation complex, CTD phospha-
tases such as FCP1 are required to dephosphorylate the
CTD of RNAP II for the reassembly of the preinitiation
complex (Archambault et al., 1998).
Tat represents a unique transcriptional activator in that
t binds to a specific RNA target and activates transcrip-
ional elongation (Jones and Peterlin, 1994; Cullen, 1993;
kamoto, 1995; Jones, 1997). It interacts with CTD ki-
ases (Parada et al., 1996; Cujec et al., 1997a; Garcia-
FIG. 3. Suppression of HIV-1 replication by NLS-mC2p peptide. (A)
Effects of NLS-mC2p on the HIV-1 production from COS cells trans-
fected with a replication-competent HIV-1 molecular clone. Various
amounts of NLS-mC2p were introduced into COS cells together with a
plasmid containing full-length HIV-1 sequence (pHXB2 or pNL4.3). After
incubation for 48 h, culture supernatants were collected and analyzed
for the concentration of viral p24 antigen in the virion using a commer-
cial ELISA kit. All data represent the means and SD values obtained
from at least three independent experiments. (B) The peptide cytotox-
icity. The cell viability was evaluated by MTT assay (shown as the
percentage of the control culture with no peptide).artinez et al., 1997b; Mancebo et al., 1997; Garriga et sl., 1997; Yang et al., 1997) and phosphatases (Marshall
t al., 1998) as well as with other cellular factors such as
at-SF1 (Zhou and Sharp, 1996). Tat might also play some
ole in the transcriptional initiation. For example, the
AL4-Tat fusion protein activates transcription from a
romoter containing GAL4 binding sites (Southgate et al.,
990). Furthermore, Tat is also known to interact with
NAP II holoenzyme (Cujec et al., 1997b), TATA-binding
rotein (Kashanchi et al., 1994), and histone acetylase
uch as CBP (Benkirane et al., 1998; Hottiger et al., 1998).
We have demonstrated in this report that the inhibition
f CDK7 by a specific peptide inhibitor was sufficient to
lock Tat transactivation and HIV-1 replication when de-
ivered to the nucleus. These results indicate that the
ction of CDK7 is indispensable for Tat action. It is
nown that TFIIH (containing CDK7) supports the CTD
hosphorylation during the promoter clearance as an
ntegral part of the preinitiation complex (Goodrich and
jian, 1994; Parada et al., 1996; Garriga et al., 1996;
ahmus, 1996; Cujec et al., 1997a). It is also known that
at interacts with CDK7 and stimulates its CTD kinase
ctivity (Cujec et al., 1997a; Garcia-Martinez et al., 1997a;
lso demonstrated in Fig. 1A). Thus, initial action of Tat in
ssociation with TFIIH is presumably the direct activa-
ion of CAK-mediated CTD phosphorylation at the level of
ranscriptional initiation. In fact, Tat was found to be
resent in the RNA polymerase II holoenzyme (Cujec et
l., 1997b) and in the preinitiation complex (Garcia-Mar-
inez et al., 1997b).
When TAR is formed within the first 59 nucleotides of
iral mRNA, Tat-TAR-cyclin T1 complex is formed and
ecruits P-TEFb (CDK9), which hyperphosphorylates CTD
hus ensuring transcriptional elongation. As TFIIH is re-
eased from the preinitiation complex during promoter
learance, recruitment of another CTD kinase such as
-TEFb is required for the progression to efficient elon-
ation. Recruitment of P-TEFb has recently been shown
ufficient for full activation of Tat transactivation using
yclin T1-Rev fusion effector and HIV/SLIIB/CAT reporter
Bieniasz et al., 1999). However, these observations do
ot exclude the possibility that Tat-mediated CAK (CDK7)
ctivation is indispensable; however, it remains to be
lucidated whether CAK directly activates P-TEFb. It is
ikely that TFIIH (CAK) and P-TEFb act sequentially to
romote CTD phosphorylation, thus supporting tran-
cription of viral mRNA by maintaining the processivity of
NAP II. However, it should be examined whether mC2p
ight inhibit another yet unknown kinase molecule that
romotes CDK2 phosphorylation and supports Tat trans-
ctivation. Alternatively, there might be CDK7 molecules
hich are not incorporated into TFIIH complex but exist
s another form and serve as a CTD kinase partner for
he Tat action.
In conclusion, our observations indicate that CAK is a
easible target for anti-HIV therapy. Although the pseudo-
ubstrate peptide of CDK7 (mC2p) by itself can be a
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341HIV-1 REPLICATION INHIBITED BY PSEUDO-SUBSTRATE PEPTIDEcandidate as an effective inhibitor of HIV-1 replication by
blocking Tat-mediated transactivation, smaller molecular
weight compounds containing similar functional moiety
are needed for a more cost-effective and practical can-
didate as a novel anti-HIV agent.
MATERIALS AND METHODS
Plasmid construction
The DNA fragment encoding nuclear localization se-
quence (NLS)-tagged mC2p was made by two synthetic
oligonucleotides, 59-GGCGAATTCGCGCCACCATGAATC-
CAAAAAAGAAGCGAAAGGTAGCCCGAGCTTTT-39, and
59-ACCGTCGACAGCTCGGTACCACAGGGTCACCACCTC-
ATGGGCGTAAGTACGTACAGGGACTCCAAAAGCTCGGG-
CTACCTTTCG-39 and cut with EcoRI and SalI, and sub-
cloned into EcoRI-SalI sites of pEGFP-N1 (CLONTECH
FIG. 4. Suppression of HIV-1 replication by a plasmid expressing N
competent HIV-1 molecular clone, pHXB2 or pNL4–3, together with pEG
of pEGFP-NLS-mC2p or its control plasmid pEGFP-NLS-rC2p (abscissa
nto COS cells. After incubation for 48 h, supernatants were collected an
f pEGFP-NLS-mC2p on cell viability. The cell viability was measured b
xpressing NLS-mC2p. Stable clones (5, 11, and 18) and parental Jurk
infection, culture supernatants were collected and the concentration of v
obtained from at least three independent experiments.Laboratories, Inc., Palo Alto, CA), a eukaryotic expres- esion plasmid for green fluorescence protein (GFP). This
plasmid was named pEGFP-NLS-mC2p. The control
plasmid pEGFP-NLS-rC2p was similarly constructed.
pZeoSV-DkB-NLSmC2p was made by inserting the ScaI-
indIII fragment of DkB-LTRCAt and the HindIII-NotI frag-
ent of pEGFP-NLSmC2p into the NsiI-NotI sites within
ZeoSV2 (Invitrogen) plasmid.
ell culture and transfection
COS cells were maintained in six-well dishes as de-
cribed (Okamoto et al., 1996). They were transfected
ith lipofectamine (Gibco BRL, Gaithersburg, MD) using
.5-mg reporter DNA (pHIVSCAT or pCMV-CAT) and 0.5
mg effector (pSVHATAT) for the CAT assay, or 1 mg HIV-1
molecular clone (pHXB2 or pNL4.3) and 0.1–0.8 mg effec-
or (pEGFP-NLSmC2p or pEGFP-NLSrC2p) for the HIV-1
eplication assay. To generate Jurkat cell clones stably
2p fused to GFP. (A) COS1 cells were transfected with a replication-
-mC2p expressing NLS-mC2p fused in-frame to GFP. Various amounts
her with a fixed amount (1 mg) of pHXB2 or pNL4–3 were transfected
ncentration of viral p24 antigen was determined as in Fig. 3. (B) Effects
assay. (C and D) Resistance of HIV-1 replication in Jurkat clones stably
were infected with HIV-1HE (C) or HIV-1IIIB (D). After 7 and 14 days of
4 antigen was determined. All data represent the means and SD valuesLS-mC
FP-NLS
) toget
d the co
y MTT
at cellsxpressing GFP-NLS-mC2p, Jurkat cells were trans-
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342 OKAMOTO ET AL.fected with linearized plasmid (pZeoSV-DkB-NLSmC2p)
and selected by 100 mg/ml Zeocin (Invitrogen, San Diego,
CA). Several stable cell lines, termed clone 5, clone 11,
and clone 18 were obtained.
Quantitative CAT assay
Transfected cells were harvested and quantitative
chloramphenicol acetyltransferase (CAT) enzymatic as-
says were done as described (Neuman et al., 1987).
Briefly, 48 h after the transfection using lipofectamine,
cells were lysed in a buffer containing 250 mM Tris/HCl,
pH 7.5, and 0.1% Triton X-100, sonicated, and the lysate
was clarified by centrifugation at 12,000 g for 15 min. CAT
activities were measured by a liquid scintillation assay
using [3H]acetyl CoA (8.1 GBq/mmol; ICN Biomedicals,
Ins., Costa Mesa, CA). As an internal control, 0.2 mg of
pCMVGal was cotransfected with CAT reporter plasmid.
Results of transient CAT expression assays were nor-
malized for transfection efficiency by b-galactosidase
activity as described (Hayashi et al., 1993). Experiments
were performed in triplicate and the results represented
by the mean values and the standard deviations.
Synthetic peptides and the subcellular localization
All peptides were synthesized by Sawady Technology
Co. (Tokyo, Japan). The peptide mC2p (Fig. 1A) was
derived from the CDK7 phosphorylation site of human
CDK2 in which threonine 160 was substituted by alanine
(Cujec et al., 1997a) to stabilize the enzyme-substrate
interaction. In NLS-mC2p, mC2p peptide was linked N-
terminally with the nuclear localization sequence (NLS)
derived from SV40 T antigen, while in NLS-rC2p the
sequence was randomized and contained the same
amino acid composition. Cytotoxicity of the peptides or
plasmids (pEGFP-mC2p or pEGFP-rC2p) was analyzed
by MTT assay and presented as a percentage of viable
cells (Sato et al., 1998). In some experiments for visual-
ization, these peptides were FITC-labeled with a com-
mercial kit (Fluorescein-C6-Amine Labeling Kit, Pan Vera
Corporation, WI). These FITC-labeled peptides were in-
troduced by lipofectamine (Gibco/BR) into COS cells as
described earlier and the subcellular localization was
examined by fluorescence microscopy.
Antiviral assays
Antiviral activity of NLS-mC2p or pEGFP-mC2p was
evaluated based on the extent of inhibition of viral anti-
gen expression in the culture supernatants of COS cells
transfected with full-length HIV-1 molecular clones
(pNL4–3 or pHXB2). These HIV-1 clones were obtained
from NIH AIDS Research and Reference Reagent Pro-
gram. For quantitative evaluation of HIV-1 viral produc-
tion, the culture supernatants were analyzed for the p24
antigen level by p24 antigen capture ELISA assay using
a commercial kit (RETRO-TEK HIV-1 p24 Antigen ELISAkit; Cellular Products Inc., NY). Jurkat cell clones stably
expressing GFP-NLS-mC2p and parental Jurkat cells
were infected with HIV-1IIIB or HIV-1HE (at multiplicity of
infection of 0. 1 TCID50 per cell). After 7 and 14 days of
infection, the culture supernatants were collected and de-
termined for their p24 antigen levels as described earlier.
In vitro kinase assay
The GST-CTD fusion protein containing 15 repeats of
the heptapeptide sequence YSPTSPS (a kind gift from
J. L. Corden) was produced in E. coli and purified on
glutathione Sepharose beads (Amersham Pharmacia
Biotech) as described (West et al., 1995; Patturajan et al.,
1997). GST-CTD proteins were eluted from the beads
using 15 mM glutathione and dialyzed against buffer D
(25 mM HEPES/KOH, pH 7.6; 0.1 M KCl; 0.1 mM EDTA; 2
mM DTT; 0.2 mM PMSF; 1 mM sodium metabisulfite; 10%
glycerol) (Dignam et al., 1983). Preparation of recombi-
nant Tat protein was described previously (Cujec et al.,
1997a,b). To obtain P-TEFb complex, nuclear extracts
derived from 293 cells stably expressing HA-tagged wild-
type CDK9/P-TEFb complex were applied to a phospho-
cellulose column (P11, Whatman) equilibrated with buffer
D containing 0.1 M KCl (Dignam et al., 1983; Garriga et al.,
1996). The column was then washed successively with
buffer D containing 0.3 and 0.5 M KCl. Protein fractions
eluted in the 0.5 M KCl (P-0.5 M) wash were combined,
dialyzed into buffer D containing 0.1 M KCl, and used for
immunoprecipitation of the HA-tagged P-TEFb complex.
P-0.5 M fractions from 293 cells served as the negative
control.
The 12CA5 monoclonal antibody detecting HA epitope
was coupled directly to protein A Sepharose beads using
dimethylpimelimidate as described (Harlow et al., 1988).
The P-0.5 M fractions were precleared with protein A
Sepharose beads and then incubated with the 12CA5-
coupled protein A Sepharose beads for 5–6 h. Immuno-
precipitates bound to the 12CA5-protein A Sepharose
beads were washed three times by binding buffer (50
mM HEPES/KOH, pH 7.6; 250 mM NaCl; 5 mM EDTA; 0.1%
Triton X-100; 5 mM DTT; 0.2 mM PMSF; 1 mM sodium
metabisulfite) and then eluted off the beads following
incubation (12 h, 4°C) with excess amounts of the 12CA5
epitope peptide (YPYDVPDYA). Typical kinase reactions
(20 mM Tris/HCl, pH 7.6; 50 mM KCl; 5 mM MgCl2; 2.5
mM MnCl2; 10 mM DTT) contained P-TEFb complex im-
munoprecipitated from 300 mg of the P-0.5 M fraction and
0 ng of the GST-CTD fusion protein. Reactions were
upplemented with 10 mCi (1 Ci 5 37 GBq) of g-ATP and
0 mM of unlabeled ATP in a final reaction volume of 50
ml. Following incubation for 1 h at 30°C, the reactions
were loaded onto SDS–PAGE (5–20% gradient). After
drying, the gels were visualized by autoradiography.
Histone H1 kinase assays were carried out according
to the method of Fisher and Morgan (Fisher et al., 1994).
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343HIV-1 REPLICATION INHIBITED BY PSEUDO-SUBSTRATE PEPTIDEBriefly, the CyclinAD171/CDK2HA complex bound to pro-
tein A Sepharose beads was incubated with either re-
combinant CAK or immunopurified P-TEFb (50 ng) (Fisher
et al., 1995). After washing the beads, the kinase activity
was evaluated based on the ability of CyclinAD171/
CDK2HA to phosphorylate histone H1 at 30°C for 1 h in
he presence of 10 mCi of g-ATP in a final reaction
olume of 50 ml. The reaction products were loaded onto
DS–PAGE (5–20% gradient). After drying, the phosphor-
lated histone H1 was visualized by autoradiography.
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